1,2:5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranoside | 3253-75-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2:5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranoside
• 英文别名: 1,2:5,6-di-O-isopropylidene-3-O-toluenesulfonyl-α-D-glucofuranose；1,2:5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranose；O¹,O²;O⁵,O⁶-diisopropylidene-O³-(toluene-4-sulfonyl)-α-D-glucofuranose；O¹,O²;O⁵,O⁶-Diisopropyliden-O³-(toluol-4-sulfonyl)-α-D-glucofuranose；1,2;5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranoside；1,2:5,6-Di-O-isopropylidene-alpha-D-glucofuranose 3-p-Toluenesulfonate；[(3aR,5R,6S,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl] 4-methylbenzenesulfonate
• CAS: 3253-75-6
• 化学式: C₁₉H₂₆O₈S
• 分子量: 414.477
• InChiKey: FOVFLADZRUACHW-NQNKBUKLSA-N

物化性质

• 沸点：
  511.3±50.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  97.9
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,2:5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranoside 在 samarium diiodide 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 以77%的产率得到3-deoxy-1,2;5,6-di-O-isopropylidene-α-D-glucofuranoside
  参考文献：
  名称：

  低价sa物种的新型光致还原体系：有机卤化物和硫属元素化物的还原及其在一氧化碳羰基化中的应用

  摘要：

  发现可见光照射可显着增强二碘化sa（SmI 2）的还原能力。通过使用此SmI 2 - hv系统，有机卤化物（RCl，RBr，RI）和硫族化物（RSPh，RSePh，RTePh）可以平滑地还原为相应的烃。光活化也可以成功地应用于二碘化（（YbI 2）。当在一氧化碳的压力下使用SmI 2 - hv系统还原烷基氯化物（RCl）时，会获得不对称的酮（RC（O）CH 2 R）作为羰基化产物。机械途径可能涉及酰基sa物种（RC（O）SmI 2），然后进行二聚化，然后用SmI 2还原，得到不对称的酮。

  DOI：

  10.1016/j.tet.2003.08.070
• 作为产物：
  描述：

  4-甲苯磺酰氰 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 生成 1,2:5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranoside
  参考文献：
  名称：

  O-Sulfinylation of alcohols with methanesulfonyl cyanide or p-toluenesulfonyl cyanide.

  摘要：

  Reaction of p-toluenesulfonyl cyanide or methanesulfonyl cyanide with alcohols in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 1,4-diazabicyclo[2.2.2]octane (DABCO) gives sulfinates in good yield. A mechanistic scheme involving sulfinyl cyanates 9 and 21 is suggested.

  DOI：

  10.1016/s0040-4020(01)96204-0

文献信息

• Synthesis of anomerically pure vinyl sulfone-modified pent-2-enofuranosides and hex-2-enopyranosides: a group of highly reactive Michael acceptors for accessing carbohydrate based synthons
  作者：Aditya Kumar Sanki、Tanmaya Pathak

  DOI：10.1016/s0040-4020(03)01059-7

  日期：2003.9

  from the derivatives of d-xylose. For the synthesis of α- and β-anomers of vinyl sulfone-modified hex-2-enopyranosides, a d-glucose derivative was selected over a d-allose derivative as the starting material because the former almost exclusively produced the required methyl pyranosides whereas the latter produced a mixture. All sulfides were converted to vinyl sulfone-modified carbohydrates by the sequential

  乙烯基砜改性的戊-2-烯呋喃糖苷的苄基或三苯甲基保护的α-和β-端基异构体的合成已通过适当掩蔽的甲基α - lyxo呋喃糖基环氧化合物或甲基β-核糖呋喃糖基环氧化合物的开环而引发。或通过苄基保护的3- O-甲苯磺酰基木糖呋喃糖苷和3- O-甲磺酰基核糖呋喃糖苷中离去基团的亲核取代被p-硫代甲酚。在后一组原料的情况下，α-和β-甲基糖苷仅由d-木糖的衍生物以几乎相等的比例形成。对于乙烯基砜改性的hex-2-enopyranosides的α和β端基异构体的合成，选择d-葡萄糖衍生物而不是d-阿洛糖衍生物作为起始原料，因为前者几乎只能生产所需的甲基吡喃糖苷，而后者产生了混合物。通过顺序应用氧化，甲磺酰化和碱诱导的消除反应，将所有硫化物均转化为乙烯基砜改性的碳水化合物。
• MONOSACCHARIDE DERIVATIVES
  申请人：Sattigeri Jitendra Viswajanani

  公开号：US20080114031A1

  公开（公告）日：2008-05-15

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了包含本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents
  申请人：Sattigeri Vishwajanani Jitendra

  公开号：US20090048186A1

  公开（公告）日：2009-02-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症和自身免疫疾病，如支气管哮喘、类风湿性关节炎、I型糖尿病、多发性硬化症、异体移植排斥、银屑病、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎。还提供了含有本发明披露的化合物的药物组合物，以及使用这些化合物治疗支气管哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症、I型糖尿病、银屑病、异体移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎以及其他炎症性和/或自身免疫障碍的方法。
• MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1842855A3

  公开（公告）日：2007-12-05

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

  本发明涉及单糖衍生物作为抗炎药物。本文中所述的化合物可用于抑制和预防炎症及相关病理，包括支气管哮喘、类风湿关节炎、1型糖尿病、多发性硬化症、移植排斥、牛皮癣、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒和过敏性鼻炎等炎症和自身免疫性疾病。还提供了含有本文披露的化合物的药理组合物以及治疗支气管哮喘、慢性阻塞性肺病、类风湿关节炎、多发性硬化症、1型糖尿病、牛皮癣、移植排斥、炎症性肠病、溃疡性结肠炎、痤疮、动脉粥样硬化、癌症、瘙痒、过敏性鼻炎和其他炎症和/或自身免疫性疾病的方法。
• Selective deprotection of terminal isopropylidene acetals and trityl ethers using HClO4 supported on silica gel
  作者：Aditi Agarwal、Yashwant D. Vankar

  DOI：10.1016/j.carres.2005.04.005

  日期：2005.7

  Terminal isopropylidene acetals are selectively cleaved to the corresponding 1,2-diols in good to excellent yields in 6-24 h at room temperature by using the 'HClO4.SiO2' reagent system. Likewise, trityl ethers are readily cleaved to the corresponding alcohols in good to excellent yields within 2-3 h at room temperature. Work-up involves merely filtration of the reagent followed by purification of

  通过使用'HClO4.SiO2'试剂系统，在室温下于6-24小时内将末端异亚丙基缩醛以良好至极好的收率选择性裂解为相应的1,2-二醇。同样，在室温下2-3小时内，三苯甲基醚很容易以良好或优异的收率裂解成相应的醇。后处理仅涉及试剂的过滤，然后纯化粗产物。